We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Device Being Developed to Detect Zika at POC

By LabMedica International staff writers
Posted on 10 Mar 2017
A handheld diagnostic device may enable detection of Zika virus accurately, rapidly, and inexpensively in many settings, even at airports as it requires only a saliva sample.

Researchers from Florida Atlantic University have been developing a diagnostic tool to reduce the impact of the Zika outbreak until a vaccine is developed. More...
“Most of the Zika cases in the United States and especially in Florida are travel related,” said Waseem Asghar, PhD, lead investigator and assistant professor at FAU, “We are working to develop a tool that can be used without expensive laboratory equipment and skilled technicians […]. For about USD 2 and within 15 minutes, we hope to accurately determine whether or not an individual has an active infection.”

Currently, patients are often diagnosed by testing blood samples for antibodies against Zika virus, however, due to cross-reaction problems the antibody test does not discriminate accurately between the Zika virus and other flaviviruses such as Dengue, West Nile virus, and Chikungunya. The more accurate method of PCR detection of viral DNA is costly, requires skilled laboratory personnel, and can take hours to yield results.

This new device is based on technology that Prof. Asghar and colleagues initially developed to detect HIV. It uses inexpensive paper- or plastic-based materials, a cassette-sized container holding up to 12 samples at a time, and a receptacle about the size of a tablet. These materials are easy to make and use, and can easily and safely be disposed of by burning, providing an appealing strategy developing, low- and middle-income countries where there is limited laboratory infrastructure.

They are currently adapting their device to diagnose the Zika virus.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.